Understanding the patient experience with CAR-T long-term follow-up (LTFU) is essential for building a sustainable model. Catalyst Healthcare Consulting, in partnership with the Emily Whitehead Foundation, surveyed nearly 100 patients and caregivers to capture their perspectives.
The findings are outlined in the whitepaper Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers, which highlights the urgent need for patient-centered LTFU processes — an increasingly critical focus as more CAR T-cell therapies receive FDA approval and reach a growing number of patients
Scientific innovation in Cell & Gene Therapy (C>) is advancing rapidly, sparking hope for patients with rare diseases, cancer, and other debilitating conditions
Being rare is often a blessing: a rare gem stands out from a pile of stones, a rare talent can garner prestige and success, and a rare personality can make for an influential leader or a cultural icon.
On Tuesday, Catalyst’s Taryn Serman and Nancy Myers, together with industry leaders, published the following article regarding women’s health on LinkedIn.
March 14th is approaching fast, and it increasingly looks like politicians are driving us toward another government shutdown.